Specify Company / Ticker to Get the Summary
Allakos Inc
ALLKAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070
Analytics
WallStreet Target Price
3.35 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALLK
Dividend Analytics ALLK
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALLK
Stock Valuation ALLK
Financials ALLK
Results | 2019 | Dynamics |